Malaria Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Malaria stocks.

Malaria Stocks Recent News

Date Stock Title
May 10 CODX Co-Diagnostics, Inc. (NASDAQ:CODX) Q1 2024 Earnings Call Transcript
May 10 TARS Tarsus Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
May 10 CODX Co-Diagnostics, Inc. (CODX) Q1 2024 Earnings Call Transcript
May 9 TARS Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
May 9 CODX Co-Diagnostics GAAP EPS of -$0.31 misses by $0.10, revenue of $0.47M misses by $2.58M
May 9 CODX Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results
May 9 TARS Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript
May 9 TARS Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
May 9 TARS Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...
May 9 TARS Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Call Transcript
May 8 TARS Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
May 8 CODX Co-Diagnostics Q1 2024 Earnings Preview
May 8 TARS Tarsus Pharmaceuticals GAAP EPS of -$1.01 beats by $0.18, revenue of $27.61M beats by $9.71M
May 8 TARS Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
May 8 AGEN Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript
May 8 SXTP 60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
May 8 AGEN Agenus First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
May 8 AGEN Agenus Inc (AGEN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...
May 7 AGEN Agenus (AGEN) Q1 2024 Earnings Call Transcript
May 7 TARS Tarsus Pharmaceuticals Q1 2024 Earnings Preview
Malaria

Malaria is a mosquito-borne infectious disease affecting humans and other animals caused by single-celled microorganisms belonging to the Plasmodium group. Malaria causes symptoms that typically include fever, tiredness, vomiting, and headaches. In severe cases it can cause yellow skin, seizures, coma, or death. Symptoms usually begin ten to fifteen days after being bitten by an infected mosquito. If not properly treated, people may have recurrences of the disease months later. In those who have recently survived an infection, reinfection usually causes milder symptoms. This partial resistance disappears over months to years if the person has no continuing exposure to malaria.The disease is most commonly transmitted by an infected female Anopheles mosquito. The mosquito bite introduces the parasites from the mosquito's saliva into a person's blood. The parasites travel to the liver where they mature and reproduce. Five species of Plasmodium can infect and be spread by humans. Most deaths are caused by P. falciparum because P. vivax, P. ovale, and P. malariae generally cause a milder form of malaria. The species P. knowlesi rarely causes disease in humans. Malaria is typically diagnosed by the microscopic examination of blood using blood films, or with antigen-based rapid diagnostic tests. Methods that use the polymerase chain reaction to detect the parasite's DNA have been developed, but are not widely used in areas where malaria is common due to their cost and complexity.The risk of disease can be reduced by preventing mosquito bites through the use of mosquito nets and insect repellents, or with mosquito control measures such as spraying insecticides and draining standing water. Several medications are available to prevent malaria in travellers to areas where the disease is common. Occasional doses of the combination medication sulfadoxine/pyrimethamine are recommended in infants and after the first trimester of pregnancy in areas with high rates of malaria. Despite a need, no effective vaccine exists, although efforts to develop one are ongoing. The recommended treatment for malaria is a combination of antimalarial medications that includes an artemisinin. The second medication may be either mefloquine, lumefantrine, or sulfadoxine/pyrimethamine. Quinine along with doxycycline may be used if an artemisinin is not available. It is recommended that in areas where the disease is common, malaria is confirmed if possible before treatment is started due to concerns of increasing drug resistance. Resistance among the parasites has developed to several antimalarial medications; for example, chloroquine-resistant P. falciparum has spread to most malarial areas, and resistance to artemisinin has become a problem in some parts of Southeast Asia.The disease is widespread in the tropical and subtropical regions that exist in a broad band around the equator. This includes much of Sub-Saharan Africa, Asia, and Latin America. In 2016, there were 216 million cases of malaria worldwide resulting in an estimated 445,000 to 731,000 deaths. Approximately 90% of both cases and deaths occurred in Africa. Rates of disease have decreased from 2000 to 2015 by 37%, but increased from 2014 during which there were 198 million cases. Malaria is commonly associated with poverty and has a major negative effect on economic development. In Africa, it is estimated to result in losses of US$12 billion a year due to increased healthcare costs, lost ability to work, and negative effects on tourism.

Browse All Tags